p73 transcriptional activity increases upon cooperation between its spliced forms

The p53 homologue p73 efficiently activates p53-responsive genes. The well documented over-expression of p73 spliced forms in a wide variety of tumor types promoted us to elucidate the mechanisms underlying p73-mediated transcription. Using the luciferase reporter gene driven by Mdm2-minimal promoter in p53 null cells, we demonstrate that the weak transcriptional activity mediated by p73α was increased by the mutant form p73β292, which by itself is transcriptionally inactive. Similarly, cooperation between p73β and an inactive form of p73α increased p73β-mediated transcriptional activities. Conversely, p73β elicited a silencing effect on a gain of function mutant, p53281, which by itself mediated efficient transactivation of the MDR promoter. Neither anisomycin nor actinomycin D altered p73-mediated transcriptional activities, whereas sorbitol profoundly inhibited them through a rapid proteasome-dependent degradation of p73. Our observations point to plausible scenarios in which p73, through cooperation between p73 spliced forms and suppression of gain of function mutant p53 may elicit changes in the transcription of p53 target genes that play key roles in cell growth and death.

[1]  C. Prives,et al.  p53: upstream, downstream and off stream. Review of the 8th p53 workshop (Dundee, July 5-9, 1996). , 1996, Biochimica et biophysica acta.

[2]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[3]  R. Camplejohn,et al.  Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members , 1998, Oncogene.

[4]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[5]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[6]  F. Haluska,et al.  Mutational and expression analysis of the p73 gene in melanoma cell lines. , 1999, Cancer research.

[7]  J. Roth,et al.  Inactivation of p53 but Not p73 by Adenovirus Type 5 E1B 55-Kilodalton and E4 34-Kilodalton Oncoproteins , 1998, Journal of Virology.

[8]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[9]  B. Gusterson,et al.  Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions , 1999, Oncogene.

[10]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[11]  A. Nakagawara,et al.  Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. , 1998, International journal of oncology.

[12]  W. Kaelin.  The emerging p53 gene family. , 1999, Journal of the National Cancer Institute.

[13]  M. Nitta,et al.  Nuclear Accumulation of p53 in Normal Human Fibroblasts Is Induced by Various Cellular Stresses which Evoke the Heat Shock Response, Independently of the Cell Cycle , 1995, Japanese journal of cancer research : Gann.

[14]  N. L. Thangue,et al.  Promoter specificity and stability control of the p53-related protein p73 , 1999, Oncogene.

[15]  K. Aldape,et al.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[17]  J. Roth,et al.  Inactivation of the p53-homologue p73 by the mdm2-oncoprotein , 1999, Oncogene.

[18]  A. Jochemsen,et al.  Distinct Regulation of p53 and p73 Activity by Adenovirus E1A, E1B, and E4orf6 Proteins , 1999, Molecular and Cellular Biology.

[19]  Xinbin Chen,et al.  The potential tumor suppressor p73 differentially regulates cellular p53 target genes. , 1998, Cancer research.

[20]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[21]  T. Halazonetis,et al.  Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. , 1998, British Journal of Cancer.

[22]  W. Liu,et al.  Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. , 1998, Genomics.

[23]  W. Kaelin,et al.  Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.

[24]  Lawrence A. Donehower,et al.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice , 1995, Nature Genetics.

[25]  S. Deb,et al.  `Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain , 1998, Oncogene.

[26]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[27]  W. Kaelin,et al.  MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.

[28]  A. Sakurada,et al.  Infrequent somatic mutations of the p73 gene in various human cancers. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  A. Nakagawara,et al.  Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. , 1998, Cancer Research.

[30]  S. Swendeman,et al.  Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[31]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[32]  J. E. Stenger,et al.  p53 oligomerization and DNA looping are linked with transcriptional activation. , 1994, The EMBO journal.

[33]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[34]  G. Melino,et al.  Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.

[35]  M. Herlyn,et al.  p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. , 1998, International journal of oncology.

[36]  T. Seyama,et al.  Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. , 1996, Cancer research.

[37]  David I. Smith,et al.  Loss of imprinting and allele switching of p73 in renal cell carcinoma , 1998, Oncogene.

[38]  J. Lotem,et al.  A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Levine,et al.  Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy , 1999, Oncogene.

[40]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[41]  D. Tindall,et al.  Mutation and expression analysis of the p73 gene in prostate cancer , 1999, The Prostate.

[42]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[43]  M. Oren.  Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven , 1997, Cell.